JP2017520577A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520577A5
JP2017520577A5 JP2016575355A JP2016575355A JP2017520577A5 JP 2017520577 A5 JP2017520577 A5 JP 2017520577A5 JP 2016575355 A JP2016575355 A JP 2016575355A JP 2016575355 A JP2016575355 A JP 2016575355A JP 2017520577 A5 JP2017520577 A5 JP 2017520577A5
Authority
JP
Japan
Prior art keywords
dosage form
layer
genus
stratified
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/038254 external-priority patent/WO2016003870A1/en
Publication of JP2017520577A publication Critical patent/JP2017520577A/ja
Publication of JP2017520577A5 publication Critical patent/JP2017520577A5/ja
Pending legal-status Critical Current

Links

JP2016575355A 2014-07-01 2015-06-29 二層二放出プロバイオティクス錠剤関連出願の相互参照 Pending JP2017520577A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462019717P 2014-07-01 2014-07-01
US62/019,717 2014-07-01
PCT/US2015/038254 WO2016003870A1 (en) 2014-07-01 2015-06-29 Bi-layer dual release probiotic tablets

Publications (2)

Publication Number Publication Date
JP2017520577A JP2017520577A (ja) 2017-07-27
JP2017520577A5 true JP2017520577A5 (enExample) 2018-08-09

Family

ID=55019868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575355A Pending JP2017520577A (ja) 2014-07-01 2015-06-29 二層二放出プロバイオティクス錠剤関連出願の相互参照

Country Status (17)

Country Link
US (1) US10799541B2 (enExample)
EP (1) EP3164145A4 (enExample)
JP (1) JP2017520577A (enExample)
KR (1) KR20170021350A (enExample)
CN (1) CN106535909A (enExample)
AP (1) AP2016009641A0 (enExample)
AU (1) AU2015284425B2 (enExample)
BR (1) BR112016031000B1 (enExample)
CA (1) CA2951739C (enExample)
CL (1) CL2016003306A1 (enExample)
MA (1) MA40071A (enExample)
MX (1) MX383492B (enExample)
PH (1) PH12016502463A1 (enExample)
RU (1) RU2736823C2 (enExample)
SG (1) SG11201610250WA (enExample)
WO (1) WO2016003870A1 (enExample)
ZA (1) ZA201608433B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN108066296B (zh) * 2016-11-11 2020-11-17 南京益恒寿生命科技有限公司 一种生物学活性组分结肠靶向组合物及其应用
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
AU2019205296B2 (en) * 2018-01-05 2021-12-23 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
EP3556226B1 (de) * 2018-04-20 2021-01-20 Raab Vitalfood GmbH Komplex-synbiotikum zum aufbau einer gesunden darmflora
CN112584848A (zh) 2018-06-18 2021-03-30 普罗比公司 益生菌组合物及其用途
AU2018428571B2 (en) 2018-06-18 2025-06-26 Probi Ab Lactobacillus plantarum compositions and uses thereof
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
WO2020181096A1 (en) * 2019-03-05 2020-09-10 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
GB201905386D0 (en) 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
GB201908154D0 (en) 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
GB201908706D0 (en) 2019-06-18 2019-07-31 Probi Ab Lactobacillus compositions and uses thereof
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
CN117159485A (zh) * 2023-08-11 2023-12-05 江中药业股份有限公司 一种益生菌香口丸及其制备方法
WO2026017258A1 (en) 2024-07-18 2026-01-22 Probi Ab Lacticaseibacillus compositions and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037953A (ja) * 1983-08-11 1985-02-27 Herusu Eido:Kk カルシウムを主成分とする栄養補助食品
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
SI0931543T1 (en) * 1997-12-19 2002-10-31 Merck Patent Gmbh Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria
JP2000302694A (ja) 1999-04-16 2000-10-31 Fuyuki Mitsuyama 医食兼用物質
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
MXPA02007254A (es) * 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
EP1151673A3 (en) 2000-05-03 2002-01-02 Societe Des Produits Nestle S.A. Confectionery product having a filling
IL156490A0 (en) 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
CA2441108A1 (en) 2001-04-05 2002-10-17 Universite Laval Process for making delivery matrix and uses thereof
US6627220B2 (en) 2001-07-13 2003-09-30 Scolr, Inc. Tablets containing heat sensitive materials and method for forming thereof
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
KR100979877B1 (ko) 2001-09-28 2010-09-02 뉴트라슈틱스 인코포레이티드 생물학적 성분의 전달 시스템
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US20030175295A1 (en) 2002-03-15 2003-09-18 Richard Ticktin Composition and method for reducing odors from metabolic processes
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20050266069A1 (en) 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
ATE514418T1 (de) * 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
WO2004087109A1 (ja) 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
KR101095712B1 (ko) 2003-08-21 2011-12-20 오츠카 세이야쿠 가부시키가이샤 점막 면역 부활 작용을 갖는 유산균
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
US20080286253A1 (en) 2004-02-09 2008-11-20 Transfert Plus Societe En Commandite Composition Comprising Polymeric Material And Uses Thereof
US20050260181A1 (en) 2004-03-05 2005-11-24 Immunopath Profile, Inc. Compositions and methods for tissue repair
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
GB0410785D0 (en) 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
US20080044481A1 (en) 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
DE102004026706A1 (de) 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
US20060062774A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal urogenital flora
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
EP1885207B1 (en) 2005-05-18 2011-07-06 DSM IP Assets B.V. Compositions for enteral application of microorganisms
SI1928426T1 (sl) 2005-09-29 2015-01-30 Merck Patent Gmbh Postopek za stabiliziranje farmacevtskih oblik za dajanje, ki vsebujejo mikroorganizme
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
SI1962873T1 (sl) 2005-12-14 2013-10-30 Oxthera Intellectual Property Ab Farmacevtski sestavki, ki vsebujejo bakterijo za zmanjšanje oksalata
US20070184111A1 (en) 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
JP5285617B2 (ja) 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
CN101815509A (zh) 2007-08-03 2010-08-25 沙克利公司 营养剂量单位
US20100239682A1 (en) 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20110223248A1 (en) 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
MY177280A (en) 2008-01-24 2020-09-10 Nestle Sa Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule
CA2721981A1 (en) 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
CN102123604A (zh) * 2008-06-24 2011-07-13 Wm.雷格利Jr.公司 益生菌口香糖的制造方法
ES2592808T3 (es) 2008-09-15 2016-12-01 Paladin Labs Inc. Micropartículas a base de almidón para la liberación de agentes dispuestos en su interior
RU2011123377A (ru) * 2008-11-14 2012-12-20 Портола Фармасьютиклз, Инк. ТВЕРДАЯ КОМПОЗИЦИЯ ДЛЯ КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ АКТИВНЫХ ИОНИЗИРУЕМЫХ АГЕНТОВ, ХАРАКТЕРИЗУЮЩИХСЯ НИЗКОЙ РАСТВОРИМОСТЬЮ В ВОДЕ ПРИ НИЗКИХ ЗНАЧЕНИЯХ pН, И СПОСОБЫ ЕЕ ПРИМЕНЕНИЯ
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
EP2381799B1 (en) 2009-01-27 2018-08-08 Probiotical S.p.a. Chocolate flavoured probiotic supplement
CA2984935C (en) 2009-02-24 2021-01-12 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
ZA201107285B (en) 2009-03-06 2012-12-27 Delivtx Inc Microencapsulated bioactive agents for oral delivery and methods of the thereof
EP2405918B2 (en) 2009-03-13 2020-09-02 The Regents of The University of California Prebiotic oligosaccharides
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
WO2011009848A2 (en) * 2009-07-20 2011-01-27 Bracco Spa Therapeutic use of probiotics
DK2459203T3 (en) 2009-07-30 2019-02-18 Dupont Nutrition Biosci Aps Lactic Acid Bacteria and Bifidobacteria for the Treatment of Endotoxemia
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ht4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CN103221420A (zh) 2010-05-19 2013-07-24 北卡罗莱纳州立大学 用于递送治疗性肽的组合物和方法
US20140154312A1 (en) 2010-09-17 2014-06-05 Monica Gulati Oral targetted drug delivery system
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
PL2685994T3 (pl) * 2011-03-17 2016-05-31 Probiotical Spa Bakterie probiotyczne wykazujące aktywność przeciwutleniającą i ich zastosowanie
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
US9308227B2 (en) 2011-05-16 2016-04-12 Organobalance Medical Ag Lactic acid bacteria and compositions containing them against bacterial colds
CN202427429U (zh) 2012-01-09 2012-09-12 北京大北农科技集团股份有限公司 一种多层微囊制备设备
US20130295227A1 (en) 2012-05-01 2013-11-07 Robbert H. ter Haar Composition Comprising a Sensitive Ingredient
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
EP2958575B1 (en) * 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Similar Documents

Publication Publication Date Title
RU2017102952A (ru) Двухслойные таблетки, содержащие пробиотики, с двойным высвобождением
JP2012144577A5 (enExample)
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
JP2014167026A5 (enExample)
JP2010509367A5 (enExample)
KR102742382B1 (ko) 경구 투약 제형
ITMI20110107A1 (it) Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
JP2014510704A5 (enExample)
CN101703513B (zh) 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂
PE20110583A1 (es) Comprimidos de capecitabina de disgregacion rapida
JP2014024874A5 (enExample)
HRP20240045T1 (hr) Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
JP2015509539A5 (enExample)
JP7050922B2 (ja) 水溶性ポリマーの接着性層
ITMI20070452A1 (it) Compressa comprendente microrganismi ed una combinazione di eccipienti e relativo procedimento di produzione
JP2017520619A5 (enExample)
JP2016512493A5 (enExample)
JP2015515974A5 (enExample)
JP5940869B2 (ja) 腸内環境改善有核錠製剤及びハードカプセル製剤
JP5957280B2 (ja) 大腸デリバリーシームレスカプセル製剤及びその製造方法
JP2015129124A5 (enExample)
WO2012067482A3 (es) COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA
CN109963565A (zh) 一种药物组合物及其制备方法
CN105106963B (zh) 马来酸曲美布汀缓释制剂及其制备方法
JP2013543881A5 (enExample)